- Home
- QLGN vs QNRX Comparison
QLGN vs QNRX Comparison
Compare QLGN & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- QNRX
- Stock Information
- Founded
- QLGN 1996
- QNRX 2018
- Country
- QLGN United States
- QNRX United States
- Employees
- QLGN N/A
- QNRX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- QLGN Health Care
- QNRX Health Care
- Exchange
- QLGN Nasdaq
- QNRX Nasdaq
- Market Cap
- QLGN 2.8M
- QNRX 3.3M
- IPO Year
- QLGN N/A
- QNRX N/A
- Fundamental
- Price
- QLGN $3.54
- QNRX $9.60
- Analyst Decision
- QLGN
- QNRX
- Analyst Count
- QLGN 0
- QNRX 0
- Target Price
- QLGN N/A
- QNRX N/A
- AVG Volume (30 Days)
- QLGN 9.1K
- QNRX 12.9K
- Earning Date
- QLGN 08-13-2025
- QNRX 08-07-2025
- Dividend Yield
- QLGN N/A
- QNRX N/A
- EPS Growth
- QLGN N/A
- QNRX N/A
- EPS
- QLGN N/A
- QNRX N/A
- Revenue
- QLGN N/A
- QNRX N/A
- Revenue This Year
- QLGN N/A
- QNRX N/A
- Revenue Next Year
- QLGN N/A
- QNRX N/A
- P/E Ratio
- QLGN N/A
- QNRX N/A
- Revenue Growth
- QLGN N/A
- QNRX N/A
- 52 Week Low
- QLGN $2.85
- QNRX $5.01
- 52 Week High
- QLGN $29.44
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- QLGN 44.87
- QNRX 64.78
- Support Level
- QLGN $3.37
- QNRX $8.04
- Resistance Level
- QLGN $3.85
- QNRX $8.58
- Average True Range (ATR)
- QLGN 0.23
- QNRX 0.46
- MACD
- QLGN -0.03
- QNRX 0.04
- Stochastic Oscillator
- QLGN 34.29
- QNRX 98.57
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.